Huggins C, Hodges CV: Studies on prostatic cancer I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941, 1:293–297.
Bologna M, Muzi P, Biordi L, et al.: Finasteride dosedependently reduces the proliferation rate of the LnCap human prostatic cancer cell line in vitro. Urology 1995, 45:282–290.
Tsukamoto S, Akaza H, Onozawa M, et al.: A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats. Cancer 1998, 82:531–537.
Thorpe JF, Jain S, Marczylo TH, et al.: A review of phase III clinical trials of prostate cancer chemoprevention. Ann R Coll Surg Engl 2007, 89:207–211.
Andriole G, Bostwick D, Brawley O, et al.: Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004, 172(4 Pt 1):1314–1317.
Dale KM, Coleman CI, Henyan NN, et al.: Statins and cancer risk: a meta-analysis. JAMA 2006, 295:74–80.
Platz EA, Leitzmann MF, Visvanathan K, et al.: Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006, 98:1819–1825.
Jacobs EJ, Rodriguez C, Bain EB, et al.: Cholesterol-lowering drugs and advanced prostate cancer incidence in a large US cohort. Cancer Epidemiol Biomarkers Prev 2007, 16:2213–2217.
Murtola T, Tammela TL, Lahtela J, Auvinen A: Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007, 16:2226–2232.
Colli JL, Amling CL: Exploring causes for declining prostate cancer mortality rates in the United States. Urol Oncol 2008, 26:627–633.
Colli JL, Amling CL: High cholesterol levels are associated with reduced prostate cancer mortality rates during periods of high but not low statin use in the United States. Urol Oncol 2008 Feb 1 (Epub ahead of print).
Schaffner CP: Prostatic cholesterol metabolism: regulation and alteration. Prog Clin Biol Res 1981, 75A:279–324.
Rosenson RS: Current overview of statin-induced myopathy. Am J Med 2004, 116:408–416.
Habel LA, Zhao W, Stanford JL: Daily aspirin use and prostate cancer risk in a large multiracial cohort in the US. Cancer Causes Control 2002, 13:427–434.
Leitzmann MF, Stampfer MJ, Ma J, et al.: Aspirin use in relation to risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2002, 11:1108–1111.
Perron L, Bairati I, Moore L, Meyer F: Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. Int J Cancer 2003, 106:409–415.
García Rodríguez LA, González-Pérez A: Inverse association between nonsteroidal anti-inflammatory drugs and prostate cancer. Cancer Epidemiol Biomarkers Prev 2004, 13:649–653.
Jacobs EJ, Rodriguez C, Mondul AM, et al.: A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst 2005, 97:975–980.
Singer EA, Palapattu GS, van Wijngaarden E: Prostatespecific antigen levels in relation to consumption of nonsteroidal anti-inflammatory drugs and acetaminophen: results from the 2001–2002 National Health and Nutrition Examination Survey. Cancer 2008, 113:2053–2057.
Penson DF, Chan JM: Prostate cancer. In Urologic Diseases in America. Edited by Litwin MS, Saigal CS. Washington, DC: US Government Publishing Office; 2007:71–122; NIH publication 07-5512.
Brawley OW: The potential for prostate cancer chemoprevention. Rev Urol 2002, 4(Suppl 5):S11–S17.
van den Brandt PA, Zeegers MPA, Bode P, Goldbohm RA: Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiol Biomarkers Prev 2003, 12:866–871.
Yoshizawa K, Willett WC, Morris SJ, et al.: Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 1998, 90:1219–1224.
Helzlsouer KJ, Huang HY, Alberg AJ, et al.: Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst 2000, 92:2018–2023.
Nomura AM, Lee J, Stemmermann GN, Combs GF Jr: Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2000, 9:883–887.
Duffield-Lillico AJ, Dalkin BL, Reid ME, et al.: Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 2003, 91:608–612.
Klein EA, Thompson IM, Lippman SM, et al.: SELECT: the selenium and vitamin E cancer prevention trial. Urol Oncol 2003, 21:59–65.
The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994, 330:1029–1035.
Colli JL, Grant WB: Solar ultraviolet B radiation compared with prostate cancer incidence and mortality rates in United States. Urology 2008, 71:531–535.
Grant WB: An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 2002, 94:1867–1875.
Giovannucci E: The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control 2005, 16:83–95.
Li H, Stampfer MJ, Hollis JB, et al.: A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med 2007, 4:e103.
Mills PK, Beeson WL, Phillips RL, Fraser GE: Cohort study of diet, lifestyle, and prostate cancer in Adventist men. Cancer 1989, 64:598–604.
Giovannucci E, Ascherio A, Rimm EB, et al.: Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 1995, 87:1767–1776.
Giovannucci E, Rimm EB, Liu Y, et al.: A prospective study of tomato products, lycopene, and prostate cancer risk. J Natl Cancer Inst 2002, 94:391–398.
Kirsh VA, Mayne ST, Peters U, et al.: A prospective study of lycopene and tomato product intake and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006, 15:92–98.
Peters U, Leitzmann MF, Chatterjee N, et al.: Serum lycopene, other carotenoids, and prostate cancer risk: a nested case-control study in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 2007, 16:962–968.
Key TJ, Appleby PN, Allen NE, et al.: Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr 2007, 86:672–681.
Kavanaugh CJ, Trumbo PR, Ellwood KC: The U.S. Food and Drug Administration’s evidence-based review for qualified health claims: tomatoes, lycopene, and cancer. J Natl Cancer Inst 2007, 99:1074–1085.
Hsing AW, Chokkalingam AP, Gao YT, et al.: Allium vegetables and risk of prostate cancer: a population based study. J Natl Cancer Inst 2002, 94:1648–1651.
Hodge AM, English DR, McCredie MR, et al.: Foods nutrition and prostate cancer. Cancer Causes Control 2004, 15:11–20.
Galeone C, Pelucchi C, Levi F, et al.: Onion and garlic use and human cancer. Am J Clin Nutr 2006, 84:1027–1032.
Colli JL, Colli A: International comparisons of prostate cancer mortality rates with dietary practices and sunlight levels. Urol Oncol 2006, 24:184–194.
Morton MS, Arisaka O, Miyake N, et al.: Phytoestrogen concentrations in serum from Japanese men and women over forty years of age. J Nutr 2002, 132:3168–3171.
Kurahashi N, Iwasaki M, Sasazuki S, et al.: Soy product and isoflavone consumption in relation to prostate cancer in Japanese men. Cancer Epidemiol Biomarkers Prev 2007, 16:538–545.
Balk E, Chung M, Chew P, et al.: Effects of soy on health outcomes. Summary, evidence report/technology assessment (no 126). Rockville, MD: Agency for Healthcare Research and Quality; 2005: AHRQ publication 05-E024-1.
Kurahashi N, Sasazuki S, Iwasaki M, et al.: Green tea consumption and prostate cancer risk in Japanese men: a prospective study. Am J Epidemiol 2008, 167:71–77.
Kikuchi N, Ohmori K, Shimazu T, et al.: No association between green tea and prostate cancer risk in Japanese men: the Ohsaki Cohort Study. Br J Cancer 2006, 95:371–373.
Jian L, Lee AH, Binns CW: Tea and lycopene protect against prostate cancer. Asia Pac J Clin Nutr 2007, 16(Suppl 1):453–457.
Jian L, Xie LP, Lee AH, Binns CW: Protective effect of green tea against prostate cancer: a case-control study in southeast China. Int J Cancer 2004, 108:130–135.